Protocol for Systematic Review on Hyperuricemia and Gout Among People Living with HIV
Approximately 39.9 million people are living with HIV globally, with a significant majority in sub-Saharan Africa. The advent of effective antiretroviral therapy (ART) has transformed HIV from a life-threatening condition into a manageable chronic disease. However, this increased longevity has brought to light new health challenges, particularly metabolic comorbidities such as hyperuricemia and gout. Recent studies suggest that integrase inhibitors, notably dolutegravir, may contribute to elevated serum uric acid levels, yet the overall burden of these conditions among people living with HIV (PLHIV) remains largely unquantified.
This protocol describes a systematic review and meta-analysis that aims to synthesize existing observational studies, including cross-sectional, cohort, and case-control studies, published up to May 2026. The review will focus on adults (aged 18 and older) living with HIV, specifically assessing the prevalence and incidence of hyperuricemia and gout. The research will involve a comprehensive search of databases such as PubMed/MEDLINE, EMBASE, Web of Science, and CINAHL. Two independent reviewers will evaluate the studies, extract relevant data, and assess the risk of bias using established appraisal tools.
The primary outcomes of the review will include the pooled prevalence of hyperuricemia and gout among PLHIV. Secondary outcomes will examine associated risk factors, including the type of ART regimen, CD4 count, viral load, duration of HIV infection, and the presence of other metabolic comorbidities. The review will also consider gout as a potential manifestation of immune reconstitution inflammatory syndrome (IRIS).
A random-effects meta-analysis will be conducted to analyze the prevalence data, with heterogeneity assessed using the I2 statistic and Cochran’s Q test. Subgroup analyses will explore variations based on ART class, geographic region, and study quality. This research is particularly relevant in the context of the increasing use of dolutegravir-based ART, which has been associated with higher rates of hyperuricemia in various cohorts.
The need for this systematic review is underscored by the lack of previous comprehensive analyses on this topic. Existing literature has primarily focused on other metabolic complications related to HIV, such as dyslipidemia and insulin resistance, without addressing urate dysregulation specifically. By framing hyperuricemia and gout under a unified concept of urate dysregulation, this review aims to provide valuable insights into the clinical management of these conditions in PLHIV, particularly in resource-limited settings where rheumatology services are scarce and misdiagnosis is common.
In summary, this systematic review and meta-analysis will fill a critical gap in understanding the prevalence and risk factors associated with hyperuricemia and gout among people living with HIV, thus informing clinical practices and monitoring strategies in the context of evolving ART regimens.




